Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

J&J’s Gorsky Stands By Remicade Longevity As Biosimilar Impact Hits Europe

This article was originally published in The Pink Sheet Daily

Executive Summary

"We expect the biosimilar market to behave quite differently" than generics, CEO Alex Gorsky says even as international sales of Remicade fell 20% in the second quarter, though largely due to currency.

Advertisement

Related Content

Hospira’s Inflectra, EU’s First Biosimilar mAb, Will Challenge Skeptics

Topics

Related Companies

Related Deals

What to read next

Advertisement
UsernamePublicRestriction

Register

PS078687

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

All set! This Question has been sent to my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel